Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
General Thoracic and Cardiovascular Surgery
Published in: General Thoracic and Cardiovascular Surgery 4/2018

01-04-2018 | Current Topics Review Article

Septal myectomy for hypertrophic cardiomyopathy: important surgical knowledge and technical tips in the era of increasing alcohol septal ablation

Authors: Yuting P. Chiang, Yuichi J. Shimada, Jonathan Ginns, Shepard D. Weiner, Hiroo Takayama

Published in: General Thoracic and Cardiovascular Surgery | Issue 4/2018

Login to get access

Abstract

Hypertrophic cardiomyopathy (HCM) is the most commonly inherited cardiac disease—recent studies suggest a prevalence as high as 1 in 200. For symptomatic patients with obstructive HCM who are refractory to medical therapy, septal reduction is indicated. Septal myectomy (SM) is considered the gold standard septal reduction technique. However, due to a shortage of surgeons who are experienced in this technique, alcohol septal ablation (ASA) has overtaken SM as the most commonly performed procedure for obstructive HCM. In this review, we summarize the existing literature comparing SM with ASA and describe recent innovations in operative technique, including a detailed description of the approach used at our institution.
Appendix
Available only for authorised users
Literature
1.
Semsarian C, Ingles J, Maron M, Maron M. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54.CrossRefPubMed
2.
Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66(11):1307–8.CrossRefPubMed
3.
Takayama H, Chung WK, Maurer MS, Ginns JN. Hypertrophic cardiomyopathy: new approaches and a time to reappraise older approaches. J Thorac Cardiovasc Surg. 2016;152(4):983–8.CrossRefPubMed
4.
Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol. 2016;13(11):651–75.CrossRefPubMed
5.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.CrossRefPubMed
6.
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733–79.CrossRefPubMed
7.
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–70.CrossRefPubMed
8.
Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol. 2016;68(25):2871–86.CrossRefPubMedCentralPubMed
9.
Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31(13):1551–3.CrossRefPubMed
10.
Ho C. Is genotype clinically useful in predicting prognosis in hypertrophic cardiomyopathy? Circulation. 2010;122:2450.CrossRef
11.
McTaggart DR, Ogden KJ, Marathe JA. A long term follow-up study of carriers of hypertrophic cardiomyopathy mutations. Heart Lung Circ. 2017;26(1):18–24.CrossRefPubMed
12.
Ho CY, McMurray JJV, Cirino AL, Colan SD, Day SM, Desai AS, et al. The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial. Am Heart J. 2017;187:145–55.CrossRefPubMedCentralPubMed
13.
Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.CrossRefPubMed
14.
Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart. 2008;94:1276–81.CrossRefPubMed
15.
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8.CrossRefPubMed
16.
Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral alterations in hypertrophic cardiomyopathy. Circulation. 1992;85(5):1651–60.CrossRefPubMed
17.
Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87(5):1570–9.CrossRefPubMed
18.
Kaple RK, Murphy RT, DiPaola LM, Houghtaling PL, Lever HM, Lytle BW, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85(5):1527–35.CrossRefPubMed
19.
Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67(15):1846–58.CrossRefPubMed
20.
Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation. 2014;130(18):1617–24.CrossRefPubMed
21.
Fifer MA. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation. 2007;16:207–16.CrossRef
22.
Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–16.CrossRefPubMed
23.
Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2011;58(22):2322–8.CrossRefPubMed
24.
Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–9.CrossRefPubMed
25.
Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AF, Willems R, Ten Cate RJ, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2(6):630–6.CrossRefPubMed
26.
Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3(11):896–905.CrossRefPubMed
27.
Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–6.CrossRefPubMed
28.
Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003–2011. JAMA Cardiol. 2016;1(3):324–32.CrossRefPubMed
29.
Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Januska J, Krejci J, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10(11):1134–43.CrossRefPubMed
30.
Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative treatment in hypertrophic subaortic stenosis. Circulation. 1975;52(1):88–102.CrossRefPubMed
31.
Schaff HV, Said SM. Transaortic extended septal myectomy for hypertrophic cardiomyopathy. Op Tech Thorac Cardiovasc Surg. 2012;17(4):238–50.CrossRef
32.
Fukuhara S, Edwards S, Kurlansky P, Takayama H. Bimanual examination for septal myectomy for hypertrophic cardiomyopathy. Interact Cardiovasc Thorac Surg. 2014;19(5):735–7.CrossRefPubMed
33.
Balaram SK, Sherrid MV, Derose JJ, Hillel Z, Winson G, Swistel DG. Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release repair. Ann Thorac Surg. 2005;80(1):217–23.CrossRefPubMed
34.
Quintana E, Schaff HV, Dearani JA. Transapical myectomy for septal hypertrophy not accessible through the aortic root. World J Pediatr Congenit Heart Surg. 2015;6(3):455–7.CrossRefPubMed
35.
Kotkar KD, Said SM, Dearani JA, Schaff HV. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann Cardiothorac Surg. 2017;6(4):329–36.CrossRefPubMedCentralPubMed
36.
Maron BJ, McIntosh CL, Klues HG, Cannon RO 3rd, Roberts WC. Morphologic basis for obstruction to right ventricular outflow in hypertrophic cardiomyopathy. Am J Cardiol. 1993;71(12):1089–94.CrossRefPubMed
37.
Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293–8.CrossRefPubMed
38.
Borisov KV. Surgical correction of hypertrophic obstructive cardiomyopathy in patients with simultaneous obstruction of left ventricular midcavity and right ventricular outflow tract. Eur J Cardiothorac Surg. 2013;43(1):67–72.CrossRefPubMed
39.
Quintana E, Johnson JN, Sabate-Rotes A, Cetta F, Ommen SR, Schaff HV, et al. Surgery for biventricular obstruction in hypertrophic cardiomyopathy in children and young adults: technique and outcomes. Eur J Cardiothorac Surg. 2015;47(6):1006–12.CrossRefPubMed
Metadata
Title
Septal myectomy for hypertrophic cardiomyopathy: important surgical knowledge and technical tips in the era of increasing alcohol septal ablation
Authors
Yuting P. Chiang
Yuichi J. Shimada
Jonathan Ginns
Shepard D. Weiner
Hiroo Takayama
Publication date
01-04-2018
Publisher
Springer Japan
Published in
General Thoracic and Cardiovascular Surgery / Issue 4/2018
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-018-0895-0

Other articles of this Issue 4/2018

General Thoracic and Cardiovascular Surgery 4/2018 Go to the issue

Case Report

Surgical case of isolated pulmonary valve endocarditis in a patient without predisposing factors

Case Report

A case of atypical type A thymoma with vascular invasion and lung metastasis

Review Article

Reconsideration of frailty in relation to surgical indication

Current Topics Review Article

Transapical approach in transcatheter cardiovascular interventions

Original Article

Usefulness of robot-assisted thoracoscopic esophagectomy

Original Article

Association between values of preoperative 6-min walk test and surgical outcomes in lung cancer patients with decreased predicted postoperative pulmonary function